Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liangjun Lu

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Antimicrobial Agents and Chemotherapy|January 24, 2008
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742Tatyana Dekhtyar, Teresa I Ng, Liangjun Lu, et al.
Nature Communications|July 7, 2025
A 4×256 Gbps silicon transmitter with on-chip adaptive dispersion compensationShihuan Ran, Yu Guo, Yuanbin Liu, et al.
AIDS Research and Human Retroviruses|March 23, 2011
Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibilityEmmanouil Magiorkinis, Dimitrios Paraskevis, Maria G Detsika, et al.
Antiviral Research|June 15, 2007
Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitroLiangjun Lu, Tatyana Dekhtyar, Sherie Masse, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2017
<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor PibrentasvirTeresa I Ng, Preethi Krishnan, Tami Pilot-Matias, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2005
Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitroHongmei Mo, Liangjun Lu, Tami Pilot-Matias, et al.
Antimicrobial Agents and Chemotherapy|December 3, 2014
In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450Tami Pilot-Matias, Rakesh Tripathi, Daniel Cohen, et al.
Viruses|August 30, 2018
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 InfectionTeresa I Ng, Tami Pilot-Matias, Rakesh Tripathi, et al.
Journal of Virological Methods|July 3, 2007
A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populationsTim Middleton, Yupeng He, Tami Pilot-Matias, et al.
Antimicrobial Agents and Chemotherapy|November 1, 2017
<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor GlecaprevirTeresa I Ng, Rakesh Tripathi, Thomas Reisch, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Antimicrobial Agents and Chemotherapy|January 24, 2008
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742Tatyana Dekhtyar, Teresa I Ng, Liangjun Lu, et al.
Nature Communications|July 7, 2025
A 4×256 Gbps silicon transmitter with on-chip adaptive dispersion compensationShihuan Ran, Yu Guo, Yuanbin Liu, et al.
AIDS Research and Human Retroviruses|March 23, 2011
Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibilityEmmanouil Magiorkinis, Dimitrios Paraskevis, Maria G Detsika, et al.
Antiviral Research|June 15, 2007
Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitroLiangjun Lu, Tatyana Dekhtyar, Sherie Masse, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2017
<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor PibrentasvirTeresa I Ng, Preethi Krishnan, Tami Pilot-Matias, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2005
Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitroHongmei Mo, Liangjun Lu, Tami Pilot-Matias, et al.
Antimicrobial Agents and Chemotherapy|December 3, 2014
In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450Tami Pilot-Matias, Rakesh Tripathi, Daniel Cohen, et al.
Viruses|August 30, 2018
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 InfectionTeresa I Ng, Tami Pilot-Matias, Rakesh Tripathi, et al.
Journal of Virological Methods|July 3, 2007
A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populationsTim Middleton, Yupeng He, Tami Pilot-Matias, et al.
Antimicrobial Agents and Chemotherapy|November 1, 2017
<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor GlecaprevirTeresa I Ng, Rakesh Tripathi, Thomas Reisch, et al.
Pageof 7